Cytomegalovirus Cell-Mediated Immunity: Ready for Routine Use?

Area of Science:

• Immunology
• Transplantation Medicine
• Virology

Background:

• Cytomegalovirus (CMV) poses significant risks in organ transplantation.
• Current CMV management relies heavily on serostatus, which has limitations.
• T-cell mediated immunity plays a crucial role in controlling CMV post-transplant.

Purpose of the Study:

• To review the role of T-cell immunity assays in managing CMV in organ transplant recipients.
• To explore how immune monitoring can personalize CMV prevention and treatment strategies.
• To assess the clinical utility and future integration of these assays in transplantation.

Main Methods:

• Review of current literature on CMV immune control post-transplantation.
• Summary of clinical experience and interventional trial outcomes using immune monitoring.
• Focus on T-cell-mediated immunity assays for CMV.

Main Results:

• T-cell immunity assays offer improved risk stratification beyond CMV serostatus.
• These assays can guide decisions on antiviral prophylaxis duration and treatment for asymptomatic replication.
• Evidence suggests these assays can identify low-risk patients, allowing safe withholding of CMV prophylaxis.

Conclusions:

• Cell-mediated immune assays are valuable tools for personalized CMV management in organ transplantation.
• These assays can optimize antiviral strategies and reduce unnecessary treatment.
• Immune monitoring assays are poised to become a routine component of clinical practice in transplantation.